Pfizer's anticoagulant Fragmin approved by FDA to treat pediatric patients with recurrent venous thrombosis

Fragmin, the anticoagulant owned by Pfizer, the global bio
pharmaceutical http://giant, was approved by theFDA(http://This is the firstdrug(http://approved for the treatment of pediatric patients with recurrent venous thrombosis (VTE)Fragmin
Fragmin is a subcutaneous injection of heparin sodium that can effectively prevent blood coagulation in cancer patients and can be used in pediatric patients who are more than a month oldAs early as 1994, the drug was approved by the FDA to prevent the risk of deep venous embolism in patients undergoing hip replacement or celiac surgeryFragmin can also be used in conjunction with aspirin to prevent local ischemic heart complications and non-Q-wave myocardial infarction attacks in patients with unstable anginaFragmin is understood to have been developed by PfizerPfizer is a global biopharmaceutical giant founded in 1849 and headquartered in New York, USAThecompany is a global leader in research and development and production capacity (http:// , with products (http:// covering the areas of chemicals, biologics, vaccines, health (http:// drugs 　　Pfizer conducted a single trial of 38 children with deep vein thrombosis and pulmonary embolism in a clinical trial (http:// These patients were treated with Fragmin for three months, and the older patients were given more doses in a single dose the end of the trial, 21 patients were stable, 7 patients improved symptoms, 2 patients did not change, and 1 patient had a recurrence safety it is understood that Fragmin's most common side effects are bleeding, including large blood discharges, platelet reduction, hematoma, pain at the injection site, and a brief increase in transaminase levels The FDA says health care providers should closely monitor bleeding in patients using Fragmin